AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
Ascentage hopes to become a new force in BTK.
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Tacti-004 is terminated for futility, and Immutep crashes 89%.
But there are no efficacy data, and the mechanism has a mountain to climb.
BPI-572270 enters clinical trials.
The company has ditched a trial of drebuxelimab plus ivonescimab.
